Advancement of Fast Skeletal Muscle Troponin Activator Expands Pipeline of Muscle-Directed Drug Candidates SOUTH SAN FRANCISCO, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated ...
Advancement of Fast Skeletal Muscle Troponin Activator Expands Pipeline of Muscle-Directed Drug Candidates SOUTH SAN FRANCISCO, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated ...
About the APEX Phase 2 Clinical Trial for TX45 in Pulmonary Hypertension with HFpEF TX45 is being evaluated in the APEX Phase 2 clinical trial (NCT06616974) in patients with Group 2 Pulmonary ...
New studies to be presented at the American Heart Association meeting focus on disparities in Wegovy prescriptions and ...
Cardiovascular disease, sometimes abbreviated as CVD, is the leading cause of death worldwide. It’s a catchall term for heart ...
Hosted on MSN2d
What Causes Congestive Heart Failure?Medically reviewed by Anisha Shah, MD Congestive heart failure (CHF) occurs when your heart muscles become damaged and can't ...
The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex ...
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported a ...
Although finerenone has kidney protective effects in patients with chronic kidney disease and type 2 diabetes, it does not appear to slow kidney function decline in patients with heart failure with ...
Risk for heart failure events is decreased and health status is improved in patients with HFmrEF and HFpEF receiving finerenone.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback